HDAC9 and lung carcinoma: First, to clarify whether a combination of anticancer drugs with different mechanisms could induce higher cell death of lung cancer cells, we used a DNA damaging agent (cisplatin (CDDP), HDAC inhibitor (LBH589) and mTOR inhibitor (rapamycin).